H. Andy Zhong

Recent Publications

For complete publication list, please click on the link and go to the NCBI webpage.

1. Almahmoud S, Elix CC, Jones JO, Hopkins CR, Vennerstrom JL, Zhong HA*. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents. Bioorg Med Chem. 2021, 46:116368. https://doi.org/10.1016/j.bmc.2021.116368 
2. Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel & Haizhen A. Zhong.* Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020), Expert Opinion on Therapeutic Patents, 2021, 31:10, 877-892, DOI:
   10.1080/13543776.2021.1924150.
3. Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery. Curr Top Med Chem. 2021;21(7):571-596. doi: 10.2174/1568026621666210119111409. PMID: 33463470.
4. Hamilton LJ, Walker M, Pattabiraman M, Zhong HA, Luedtke B, Chandra S. Novel curcumin analog (Cis-Trans Curcumin) as ligand to adenosine receptors A_2A and A_2B: potential for therapeutics. Pharmacol Res. 2021 Mar;165:105410. doi: 10.1016/j.phrs.2020.105410. Epub 2021 Jan 2. PMID: 33401004.
5. Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA. An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors. Curr Top Med Chem. 2021; 21(6):442-460. doi: 10.2174/1568026620666201207095117. PMID: 33292134.
6. Sabbah DA, Hajjo R, Sweidan K, Zhong HA. An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors. Curr Comput Aided Drug Des. 2020 Aug 19. doi: 10.2174/1573409916666200819113444. Epub ahead of print. PMID: 32814537.
7. Zhong HA. Structure-based Design on Anticancer Drug Discovery. Curr Top Med Chem. 2020;20(10):813-814. doi: 10.2174/156802662010200331100200. PubMed PMID: 32463006.
8. Wani RJ, Sharma P, Zhong HA, Chauhan H. Preparation and Characterization of Griseofulvin Solid Dispersions. Assay Drug Dev Technol. 2020 Apr;18(3):109-118. doi: 10.1089/adt.2019.965. PubMed PMID: 32319818.
9. Almahmoud S, Jin W, Geng L, Wang J, Wang X, Vennerstrom JL, Zhong HA. Ligand-based design of GLUT inhibitors as potential antitumor agents. Bioorg Med Chem. 2020 Apr 1;28(7):115395. doi: 10.1016/j.bmc.2020.115395. Epub 2020 Feb 18. PubMed PMID: 32113844
10. Almahmoud S, Zhong HA. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. Int. J. Mol. Sci., 2019, 20, 4654.  doi:10.3390/ijms20184654.
11. Daszynski DM, Santhoshkumar P, Phadte AS, Sharma KK, Zhong HA, Lou MF, Kador PF. Failure of Oxysterols Such as Lanosterol to Restore Lens Clarity from Cataracts. Sci Rep. 2019 Jun 11; 9(1):8459. doi: 10.1038/s41598-019-44676-4.
12. Almahmoud S, Wang X, Vennerstrom JL, Zhong HA*. Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target. Molecules. 2019 Jun 7;24(11). pii: E2159. doi: 10.3390/molecules24112159.
13. Sabbah DA, Ibrahim AH, Talib WH, Alqaisi KM, Sweidan K, Bardaweel SK, Sheikha GA, Zhong HA, Al-Shalabi E, Khalaf RA, Mubarak MS. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents. Med Chem. 2019, 15, 417-429. doi: 10.2174/1573406414666180912111846.
14. Zhong HA, Santos EM, Vasileiou C, Zheng Z, Geiger JH, Borhan B, Merz KM Jr. Free-Energy-Based Protein Design: Re-Engineering Cellular Retinoic Acid Binding Protein II Assisted by the Moveable-Type Approach. J Am Chem Soc. 2018 Mar 14;140(10):3483-3486. doi: 10.1021/jacs.7b10368. Epub 2018 Feb 28..
15. Xianting Cao, Haizhen A. Zhong, Pengfei Zhang, and Hui Zheng. The Simple System of Fixing CO2 to Synthesize Benzimidazolones at Atmospheric Pressure. Journal of CO2 Utilization, 2018, 24, 250-255.
16. Sabbah DA, Al-Tarawneh F, Talib W, Sweidan K, Bardaweel S, Al-Shalabi E, Zhong HA, Abu Sheikha G, Abu Khalaf R, Mubarak MS. Benzoin Schiff Bases: Design, Synthesis, and Biological Evaluation as Potential Antitumor Agents. Medicinal Chemistry. 2018, 14 (7), 695-708; doi: 10.2174/1573406414666180412160142.
17. Sabbah DA, Hishmah B, Sweidan K, Bardaweel S, AlDamen M, Zhong HA, Abu Khalaf R, Ibrahim AH, Al-Qirim T, Abu Sheikha G, Mubarak MS. Structure-Based Drug Design: Synthesis, X-Ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential PI3Kα Inhibitors. Anticancer Agents Med Chem. 2018, 18(2), 263-276. doi: 10.2174/1871520617666170911171152.
18. Kumar V, Chaudhary AK, Dong Y, Zhong HA, Mondal G, Lin F, Kumar V, Mahato RI. Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Sci Rep. 2017 May 10; 7(1):1665. doi: 10.1038/s41598-017-01942-7. 
19. Udumula V, Endres JL, Harper CN, Jaramillo L, Zhong HA, Bayles KW, Conda-Sheridan M. Simple synthesis of endophenazine G and other phenazines and their evaluation as anti-methicillin-resistant Staphylococcus aureus agents. Eur J Med Chem. 2017, 125:710-721. doi: 10.1016/j.ejmech.2016.09.079. Epub 2016 Sep 28. 
20. Sabbah DA, and Zhong HA. Modeling the protonation states of β-secretase binding pocket by molecular dynamics simulations and docking studies. J. Mol. Graphics & Modeling., 2016, 68, 206-215 
21. Sabbah DA, Hu J, Zhong HA. Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors. Curr. Top. Med. Chem., 2016, 16, 1413-26. 
22. Xu D, Li R, Wu J, Jiang L, Zhong HA. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway. Curr. Top. Med. Chem., 2016, 16, 1441-51. 
23. Ehlers T, Furness S, Robinson TP, Zhong HA, Goldsmith D, Arbiser J, Bowen JP. Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis. Curr. Top. Med. Chem., 2016, 16 (13), 1478-88. 

Book Chapters

1. Zhong HA. ADMET Properties: Overview and Current Topics. Chapter 8, Pages 113-133. Book, Drug Design: Principles and Applications. Editor, Abhinav Grover, Publisher: Springer Nature; 2017. ISBN 978-981-10-5187-6. DOI 10.1007/978-981-10-5187-6_8.
2. Zhong HA, Güner OF, Bowen JP. Book Chapter, Chapter 20, "Rational Drug Discovery, Design, and Development" (pages 443-464), in Book titled Drug Delivery: Fundamentals and Applications, Second Edition ISBN 9781482217711 - CAT# K22118, CRC Press, Editors: Anya M Hillery, Kinam Park. (2016)
3. Zhong HZ, and Bowen JP. Computer-assisted drug design. Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition DOI: 10.1081/E-EPT4-120050222. July, 2013. Pages, 620-633. Informa plc (Switzerland)
4. Bowen JP and Zhong HZ. Computational Chemistry. Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition DOI: 10.1081/E-EPT4-120050220. July, 2013, Pages, 600-614. Informa plc (Switzerland)
5. Zhong HZ, Lee M, Bowen JP, “Modeling and Simulations of Nucleic Acids and Their Complexes”. In Book "Synthetic and Biophysical Studies of DNA Binding Compounds." Editors: Moses Lee and Lucjan Strekowski, ISBN: 978-81-7895-290-1.  Transworld Research Network, Kerala, India (2007: pages 93-129).

Editorial Service:

Guest Editor, Structure-based Design on Anticancer Drug Discovery. Current Topics in Medicinal Chemistry, 2020, Vol. 20, Issue 10. 

Editorial Board Member, Journal of Molecular Graphics & Modelling (2020-present)

Review Board Member, Cancers (2020-present)

Honor:

Excellence in Research/Creative Activity Award, College of Arts and Sciences, University of Nebraska at Omaha, 2020.